Cancer Drugs Under Development
According to the Pharmaceutical Research and Manufacturers of America, as of 1993, 124 cancer drugs were in some stage of development at 49 pharmaceutical companies and the National Cancer Institute. The report was based on an NCI survey.
According to the Pharmaceutical Research and Manufacturers ofAmerica, as of 1993, 124 cancer drugs were in some stage of developmentat 49 pharmaceutical companies and the National Cancer Institute.The report was based on an NCI survey. At least 16 of the upcomingcancer drugs are genetically engineered. Since many of these drugsare targeted to more than one type of cancer, 223 research projectsare ongoing.
Articles in this issue
New Noninvasive Test May Improve Breast Cancer Diagnosis and Reduce Unnecessary Biopsies
Cancer Drugs Under Development
Early Results of RTOG Small-Cell Lung Cancer Trial
The Economics of Oncology: Health System Reform and Clinical Research
An Update on the Pros and Cons of Preventive Mastectomy
The Effect of Tamoxifen on the Endometrium
Commentary (Look): The Effect of Tamoxifen on the Endometrium
Commentary (Kimmick/Muss): The Effect of Tamoxifen on the Endometrium
Management of Papillary Thyroid Cancer
Commentary (Cady): Management of Papillary Thyroid Cancer
The Management of Early Ovarian Cancer
Commentary (Markman): The Management of Early Ovarian Cancer
Commentary (Thigpen): The Management of Early Ovarian Cancer
Recent Videos
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
